Clinical Trial Update: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating combinations of sorafenib with erlotinib, tipifarnib, or temsirolimus in adults with recurrent glioblastoma multiforme or gliosarcoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Sorafenib (Sorafenib)
• Temsirolimus (temsirolimus)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-07-02